AACR 2020 | sciencenewsnet.in

Breaking News

These jacks-of-all-trades are masters, too: Yeast study helps answer age-old biology question

Living with Stage 3 lung cancer in your 80s and 90s

ETRI published Key International Standards for Wearable Healthcare

Study Unveils Balance of AI and Preserving Humanity in Health Care

Press Registration for the ASRS 2024 Annual Scientific Meeting Now Open

A systematic review of three key sugar metabolism proteins, HXK, SnRK1 and TOR, in the regulatory network of plant growth, development and stress

Orchid Welcomes Distinguished Clinical and Genetics Leaders to its Advisory Boards

Potential new worlds rescued by citizens of Earth! Early results of people-powered astronomy project ‘out of this world’

Genetic variations may predispose people to Parkinson’s disease following long-term pesticide exposure, study finds

BIMM University chooses Figshare to showcase its non-traditional research and creative practitioner outputs

25 Apr, 2024

MSK Physician-Scientists Recognized with Top Honors by AACR, ASCO, and ASH Organizations

June 23, 2020 sarah JonasAnnouncement

Memorial Sloan Kettering Cancer Center (MSK) announces the following awards and honors to our staff, given by the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and the American Society of Hematology (ASH) organizations.

St. Jude Children’s Research Hospital president, CEO recognized for contributions to cancer research

June 22, 2020 sarah JonasAnnouncement

The American Association for Cancer Research honored St. Jude President and CEO James R. Downing, M.D., with its inaugural AACR-St. Baldrick’s Foundation Award for Outstanding Achievement in Pediatric Cancer Research.

Superior Progression-Free Survival Associated with Continuous Targeted Therapy Combination for BRAF-mutated Melanoma

April 27, 2020 sarah JonasResearch Results

Results from a randomized phase 2 clinical trial examining the targeted therapy drugs dabrafenib and tremetinib in both continuous and intermittent treatment of patients with BRAF-mutated melanoma show continuous dosing yields superior progression free survival. A Rutgers Cancer Institute of New Jersey investigator shares more on the work presented at the opening plenary session of the virtual AACR Annual Meeting.